Advertisement

Lung

, Volume 196, Issue 5, pp 577–581 | Cite as

Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Review and a Single Center Experience

  • Zin W. Myint
  • James McCormick
  • Aman Chauhan
  • Elizabeth Behrens
  • Lowell B. Anthony
INTERSTITIAL LUNG DISEASE

Abstract

Background

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare pulmonary condition, characterized by diffuse proliferation of neuroendocrine cells in the respiratory epithelium. DIPNECH lesions are less than 5 mm in size and are limited to the basement membrane with no invasion. There is limited information regarding epidemiology, natural history of disease progression, or the management of this rare entity. We present the experience of a center with extensive expertise in neuroendocrine disease.

Methods

A cohort of patients (N = 13) with DIPNECH treated and followed at our institution was identified. We describe the our approach to their care, our disease management and also provide a review of DIPNECH pathophysiology.

Results

Our patient cohort consisted of twelve females and one male with a mean age of 63 years at the time of diagnosis. Dyspnea on exertion and dry cough were the most common presenting symptoms. Two patients were under surveillance without treatment; three patients were treated with a short-acting somatostatin analog; three patients were treated with azithromycin alone; four were treated with a combination of long-acting monthly somatostatin analogs and azithromycin; one patient received a combination of long-acting somatostatin analog and everolimus. Five patients had concomitant bronchial carcinoids.

Conclusions

DIPNECH is a rare pathology that can profoundly affect a patient’s quality of life. Paroxysmal coughing episodes can be difficult to treat. Our limited single center experience shows encouraging response to use of somatostatin analogs, azithromycin, and everolimus in the management of debilitating DIPNECH associated symptoms.

Keywords

DIPNECH Octreotide Azithromycin Everolimus 

Notes

Acknowledgements

The authors thank Catherine Anthony, Ph.D. for assistance with manuscript preparation.

Author Contributions

Conception and design: All authors; Administrative support: LA; Provision of materials: All authors; Collection and assembly of data: ZM and AC; Data interpretation: ZM; Manuscript writing and final approval: All authors.

Compliance with Ethical Standards

Conflict of interest

No author has any conflict of interest to declare.

References

  1. 1.
    Aguayo SM, Miller YE, Waldron JA Jr et al (1992) Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med 327(18):1285–1288CrossRefPubMedGoogle Scholar
  2. 2.
    Gorshtein A, Gross DJ, Barak D et al (2012) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entity. Cancer 118(3):612–619CrossRefPubMedGoogle Scholar
  3. 3.
    Kerr KM (2001) Pulmonary preinvasive neoplasia. J Clin Pathol 54(4):257–271CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) Tumors of the lung. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (eds) WHO classification of tumors of the lung, pleural, thumus and heart, vol 7, 4th edn. International Agency for Reseach on Cancer, Lyon, pp 73–79Google Scholar
  5. 5.
    Wirtschafter E, Walts AE, Liu ST, Marchevsky AM (2015) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia of the lung (DIPNECH): current best evidence. Lung 193(5):659–667CrossRefPubMedGoogle Scholar
  6. 6.
    Nassar AA, Jaroszewski DE, Helmers RA, Colby TV, Patel BM, Mookadam F (2011) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a systematic overview. Am J Respir Crit Care Med 184(1):8–16CrossRefPubMedGoogle Scholar
  7. 7.
    Hospital and University Center of Coimbra (2015) http://www.chuc.min-saude.pt. Accessed Jan 2018
  8. 8.
    Davies SJ, Gosney JR, Hansell DM et al (2007) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 62(3):248–252CrossRefPubMedGoogle Scholar
  9. 9.
    Koo CW, Baliff JP, Torigian DA, Litzky LA, Gefter WB, Akers SR (2010) Spectrum of pulmonary neuroendocrine cell proliferation: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, tumorlet, and carcinoids. AJR Am J Roentgenol 195(3):661–668CrossRefPubMedGoogle Scholar
  10. 10.
    Travis WD (2010) Advances in neuroendocrine lung tumors. Ann Oncol 21(Suppl 7):765–771Google Scholar
  11. 11.
    Chauhan A, Ramirez RA (2015) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and the role of somatostatin analogs: a case series. Lung 193(5):653–657CrossRefPubMedGoogle Scholar
  12. 12.
    Song H, Yao E, Lin C, Gacayan R, Chen MH, Chuang PT (2012) Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci USA 109(43):17531–17536CrossRefPubMedGoogle Scholar
  13. 13.
    Feyrter F (1938) Uber diffuse endocrine epitheliale organe. J. A. Bath, LeipzigGoogle Scholar
  14. 14.
    Lundgren JD, Baraniuk JN, Ostrowski NL, Kaliner MA, Shelhamer JH (1990) Gastrin-releasing peptide stimulates glycoconjugate release from feline trachea. Am J Physiol 258(2 Pt 1):L68–L74PubMedGoogle Scholar
  15. 15.
    Impicciatore M, Bertaccini G (1973) The bronchoconstrictor action of the tetradecapeptide bombesin in the guinea-pig. J Pharm Pharmacol 25(11):872–875CrossRefPubMedGoogle Scholar
  16. 16.
    Dhungana S, McCormick J (2014) Successful treatment of DIPNECH with azithromycin. Chest 146(4):80ACrossRefGoogle Scholar
  17. 17.
    Susini C, Buscail L (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17(12):1733–1742CrossRefPubMedGoogle Scholar
  18. 18.
    Bousquet C, Lasfargues C, Chalabi M et al (2012) Clinical review: current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab 97(3):727–737CrossRefPubMedGoogle Scholar
  19. 19.
    Rossi G, Cavazza A, Graziano P, Papotti M (2012) mTOR/p70S6K in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Am J Respir Crit Care Med 185(3):341. (author reply 341–342)CrossRefPubMedGoogle Scholar
  20. 20.
    Righi L, Volante M, Rapa I et al (2010) Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 17(4):977–987CrossRefPubMedGoogle Scholar
  21. 21.
    Mourad MR, Hamblin MJ (2015) Sirolimus for the treatment of diffuse idiopathic pulmonary neuroendocrine cell Hyperplasia (DIPNECH). A38. Tell me what you see: atypical presentations of ild. Am Thorac Soc 2015:A1501–A1501Google Scholar
  22. 22.
    Zhou H, Ge Y, Janssen B et al (2014) Double lung transplantation for diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. J Bronchol Interv Pulmonol 21(4):342–345CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Zin W. Myint
    • 1
  • James McCormick
    • 2
  • Aman Chauhan
    • 1
  • Elizabeth Behrens
    • 3
  • Lowell B. Anthony
    • 1
  1. 1.Division of Medical Oncology, Department of Internal MedicineUniversity of KentuckyLexingtonUSA
  2. 2.Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal MedicineUniversity of KentuckyLexingtonUSA
  3. 3.College of MedicineUniversity of KentuckyLexingtonUSA

Personalised recommendations